Skip to Main Content

Paper Details

The Q61H mutation decouples KRAS from upstream regulation and renders cancer cells resistant to SHP2 inhibitors.
Nat Commun
22
2021
Cancer, Cancer cells, ERK, GAP, GEF, GTP, KRAS, KRAS Q61H, KRAS Q61H cells, KRAS mutations, Q61H, Q61H mutant, Q61H-mutant KRAS, RAF, SHP2, SHP2i, SOS1, Src, Tyr32, Tyr64, cancer, cancer cells, tyrosyl, wild-type and Gly12-mutant KRAS
Author NameAffiliation
Zhong-Yin ZhangCenter for Cancer Research and Institute for Drug Discovery, Purdue University
Zhong-Yin ZhangCenter for Cancer Research and Institute for Drug Discovery, Purdue University
Ming-Sound TsaoPrincess Margaret Cancer Centre, University Health Network
Ming-Sound TsaoUniversity of Toronto
Ming-Sound TsaoUniversity of Toronto
Brian RaughtPrincess Margaret Cancer Centre, University Health Network
Brian RaughtUniversity of Toronto
  • 1 - 7

Datasets

Release 1.2